-transparent.png){kind=logo}
Chronic myelogenous leukemia (CML) expresses two types of bcr-abl chimeric mRNA. One is b3a2 type in which bcr exon 3 binds to abl exon 2, the other is b2a2 type that bcr exon 2 binds to abl exon 2. Either bcr-abl is normally expressed, but both types of bcr-abl mRNA can be expressed at the same time in a patient. We report here a rare case of CML expressing two types of bcr-abl mRNA and discuss the possibility that this double expression would help to monitor the clinical course of CML.
Related Publications
S Hashimoto, and
M Hiyoshi, and
M Hino, and
T Yamane, and
T Ota, and
K R Koh, and
S Tagawa, and
N Tatsumi
August 2002,
Haematologica,
S Hashimoto, and
M Hiyoshi, and
M Hino, and
T Yamane, and
T Ota, and
K R Koh, and
S Tagawa, and
N Tatsumi
December 1991,
Transplantation,
S Hashimoto, and
M Hiyoshi, and
M Hino, and
T Yamane, and
T Ota, and
K R Koh, and
S Tagawa, and
N Tatsumi
July 1996,
Leukemia research,
S Hashimoto, and
M Hiyoshi, and
M Hino, and
T Yamane, and
T Ota, and
K R Koh, and
S Tagawa, and
N Tatsumi
October 1994,
Blood,
S Hashimoto, and
M Hiyoshi, and
M Hino, and
T Yamane, and
T Ota, and
K R Koh, and
S Tagawa, and
N Tatsumi
January 2005,
Zhonghua yi xue za zhi,
S Hashimoto, and
M Hiyoshi, and
M Hino, and
T Yamane, and
T Ota, and
K R Koh, and
S Tagawa, and
N Tatsumi
February 2017,
Oncotarget,
S Hashimoto, and
M Hiyoshi, and
M Hino, and
T Yamane, and
T Ota, and
K R Koh, and
S Tagawa, and
N Tatsumi
August 2001,
Journal of Nippon Medical School = Nippon Ika Daigaku zasshi,
S Hashimoto, and
M Hiyoshi, and
M Hino, and
T Yamane, and
T Ota, and
K R Koh, and
S Tagawa, and
N Tatsumi
July 2007,
The New England journal of medicine,
S Hashimoto, and
M Hiyoshi, and
M Hino, and
T Yamane, and
T Ota, and
K R Koh, and
S Tagawa, and
N Tatsumi
June 1995,
Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine,
S Hashimoto, and
M Hiyoshi, and
M Hino, and
T Yamane, and
T Ota, and
K R Koh, and
S Tagawa, and
N Tatsumi
March 1987,
Blood,
